

Sandro Pignata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6623824/publications.pdf>

Version: 2024-02-01

228
papers

13,906
citations

31976

53
h-index

24258

110
g-index

236
all docs

236
docs citations

236
times ranked

13360
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group). <i>Immunotherapy</i> , 2022, 14, 107-114.	2.0	4
2	Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment. <i>European Journal of Cancer</i> , 2022, 161, 55-63.	2.8	3
3	Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 437-448.	27.0	375
4	Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. <i>Gynecologic Oncology</i> , 2022, 164, 254-264.	1.4	51
5	Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 799-803.	2.5	2
6	A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1205-1207.	2.5	5
7	Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients. <i>Cancers</i> , 2022, 14, 1849.	3.7	3
8	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022, 7, 100459.	4.5	26
9	Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	4
10	Evaluation of perioperative management of advanced ovarian (tubal/peritoneal) cancer patients: a survey from MITO-MaNGO Groups. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	1
11	Reirradiation of Locally Recurrent Prostate Cancer with Cyberknife® System or Volumetric Modulated Arc Therapy (VMAT) and IGRT-Clarity®: Outcomes, Toxicities and Dosimetric Evaluation. <i>Cancers</i> , 2022, 14, 3187.	3.7	3
12	From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer. <i>Immunotherapy</i> , 2021, 13, 67-77.	2.0	2
13	A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer. <i>Oncologist</i> , 2021, 26, e658-e668.	3.7	13
14	Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM). <i>Tumori</i> , 2021, 107, 100-109.	1.1	8
15	Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 110-113.	2.5	3
16	Cytological diagnosis of Xp11 translocation renal cell carcinoma: An unusual suspect in bone metastases from unknown primary malignancies. <i>Diagnostic Cytopathology</i> , 2021, 49, 11-17.	1.0	1
17	An Italian National Survey on Ovarian Cancer Treatment at first diagnosis. There's None so Deaf as those who will not Hear. <i>Journal of Cancer</i> , 2021, 12, 4443-4454.	2.5	5
18	How to sequence treatment in relapsed ovarian cancer. <i>Future Oncology</i> , 2021, 17, 1-8.	2.4	1

#	ARTICLE	IF	CITATIONS
19	Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2021, 22, 267-276.	10.7	79
20	Prognostic Evidence of the miRNA-Based Ovarian Cancer Signature MiROvaR in Independent Datasets. <i>Cancers</i> , 2021, 13, 1544.	3.7	4
21	Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 875-882.	2.5	19
22	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)., 2021, 9, e002619.		17
23	Efficacy and safety of tisetumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2021, 22, 609-619.	10.7	186
24	Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, ijgc-2020-002343.	2.5	4
25	Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021, 22, 620-631.	10.7	215
26	Surveillance alone in stage I malignant ovarian germ cell tumors: a MITO (Multicenter Italian Trials in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2021, 31, 1242-1247.	2.5	8
27	Real-world experience with trabectedin for the treatment of recurrent ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1089-1095.	2.4	4
28	Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21). <i>Gynecologic Oncology</i> , 2021, 161, 755-761.	1.4	9
29	Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). <i>Journal of Clinical Oncology</i> , 2021, 39, 1842-1855.	1.6	183
30	Response to letter entitled: Re: Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis. <i>European Journal of Cancer</i> , 2021, 152, 257-258.	2.8	1
31	Stage I juvenile granulosa cell tumors of the ovary: A multicentre analysis from the MITO-9 study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1705-1709.	1.0	8
32	Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1348-1355.	2.5	3
33	Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1363-1368.	2.5	3
34	The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas. <i>Cancer Treatment Reviews</i> , 2021, 100, 102294.	7.7	21
35	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110196.	3.2	36
36	Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1369-1373.	2.5	12

#	ARTICLE	IF	CITATIONS
37	Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study. <i>Cancers</i> , 2021, 13, 5152.	3.7	7
38	Olaparib as maintenance therapy in patients with BRCA 1&2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome. <i>Gynecologic Oncology</i> , 2020, 156, 38-44.	1.4	62
39	Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing. <i>Journal of Clinical Oncology</i> , 2020, 38, 172-173.	1.6	6
40	A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. <i>Oncologist</i> , 2020, 25, e311-e320.	3.7	56
41	Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer. <i>JAMA Network Open</i> , 2020, 3, e1918939.	5.9	40
42	Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors. <i>JAMA Oncology</i> , 2020, 6, 1923.	7.1	27
43	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096846.	3.2	14
44	Clinical trials and drug cost savings for Italian health service. <i>BMC Health Services Research</i> , 2020, 20, 1089.	2.2	7
45	The clinical and translational research activities at the INT - IRCCS - Fondazione Pascale cancer center (Naples, Italy) during the COVID-19 pandemic. <i>Infectious Agents and Cancer</i> , 2020, 15, 69.	2.6	8
46	European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and industry partners - a new Model D for drug and medical device development. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 730-734.	2.5	3
47	Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis. <i>European Journal of Cancer</i> , 2020, 137, 136-143.	2.8	17
48	Immunotherapy in cervix cancer. <i>Cancer Treatment Reviews</i> , 2020, 90, 102088.	7.7	28
49	&p>PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6123-6135.	1.9	25
50	Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience. <i>Cancers</i> , 2020, 12, 2239.	3.7	6
51	Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment. <i>Cancer Treatment Reviews</i> , 2020, 90, 102107.	7.7	21
52	Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study. <i>Scientific Reports</i> , 2020, 10, 18190.	3.3	16
53	Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. , 2020, 8, e001154.		13
54	COVID-19 Emergency and Post-Emergency in Italian Cancer Patients: How Can Patients Be Assisted?. <i>Frontiers in Oncology</i> , 2020, 10, 1571.	2.8	14

#	ARTICLE	IF	CITATIONS
55	MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. <i>Journal of Clinical Oncology</i> , 2020, 38, 3753-3762.	1.6	82
56	Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2020, 87, 102040.	7.7	35
57	PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?. <i>Frontiers in Oncology</i> , 2020, 10, 782.	2.8	11
58	Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?. <i>Journal of Clinical Medicine</i> , 2020, 9, 1721.	2.4	43
59	Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience. <i>Cells</i> , 2020, 9, 903.	4.1	8
60	Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6002-6002.	1.6	75
61	Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e92.	2.2	20
62	Patterns of progression and subsequent management of patients with <i>BRCA1/2</i> mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353).. <i>Journal of Clinical Oncology</i> , 2020, 38, 6070-6070.	1.6	4
63	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , 2019, 123, 98-105.	2.5	70
64	Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives. <i>Journal of Clinical Oncology</i> , 2019, 37, 2437-2448.	1.6	96
65	Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group. <i>Future Oncology</i> , 2019, 15, 2657-2666.	2.4	1
66	Joint ENGOT and GOG Foundation requirements for trials with industry partners. <i>Gynecologic Oncology</i> , 2019, 154, 255-258.	1.4	7
67	Management of kidney cancer ep patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). <i>Tumori</i> , 2019, 105, 3-12.	1.1	10
68	Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors. <i>Cancers</i> , 2019, 11, 1584.	3.7	16
69	BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories. <i>Diagnostics</i> , 2019, 9, 146.	2.6	3
70	Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 67-72.	4.4	51
71	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 862-876.	10.7	68
72	State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 87-90.	4.4	21

#	ARTICLE	IF	CITATIONS
73	Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials. <i>Gynecologic Oncology</i> , 2019, 154, 83-88.	1.4	9
74	The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2019, 153, 535-540.	1.4	19
75	Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 430-433.	2.5	33
76	Joint ENGOT and GOG Foundation requirements for trials with industry partners. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1094-1097.	2.5	6
77	Treatment of recurrent epithelial ovarian cancer. <i>Cancer</i> , 2019, 125, 4609-4615.	4.1	49
78	Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. <i>Frontiers in Oncology</i> , 2019, 9, 1289.	2.8	10
79	Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications. <i>Cancers</i> , 2019, 11, 1820.	3.7	57
80	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2416-2428.	27.0	1,176
81	Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591881835.	3.2	13
82	Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology. <i>PLoS ONE</i> , 2019, 14, e0210330.	2.5	6
83	PARP inhibitors in ovarian cancer. <i>Cancer Treatment Reviews</i> , 2019, 73, 1-9.	7.7	158
84	Sequencing chemotherapy and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (UC): Meet-Uro1 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16013-e16013.	1.6	1
85	Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer. <i>Annals of Oncology</i> , 2018, 29, 1189-1194.	1.2	8
86	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, 404-416.	0.6	241
87	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 641-655.	2.5	336
88	Evaluation of a Streamlined Oncologist-Led <i>BRCA</i> Mutation Testing and Counseling Model for Patients With Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1300-1307.	1.6	76
89	Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 297.	8.6	11
90	Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24). <i>Targeted Oncology</i> , 2018, 13, 469-479.	3.6	38

#	ARTICLE	IF	CITATIONS
91	Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy. PLoS ONE, 2018, 13, e0199642.	2.5	23
92	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget, 2018, 9, 19861-19873.	1.8	37
93	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 919-936.	2.8	127
94	Obesity and Cancer: Biological Links and Treatment Implications. Current Cancer Drug Targets, 2018, 18, 231-238.	1.6	19
95	Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.. Journal of Clinical Oncology, 2018, 36, 5506-5506.	1.6	55
96	Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.. Journal of Clinical Oncology, 2018, 36, 5511-5511.	1.6	45
97	ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. European Journal of Cancer, 2017, 70, 111-121.	2.8	70
98	Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project. Supportive Care in Cancer, 2017, 25, 1743-1748.	2.2	1
99	Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancerâ€™The GCIG Symptom Benefit Study. Oncologist, 2017, 22, 1117-1124.	3.7	20
100	Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. Gynecologic Oncology, 2017, 144, 256-259.	1.4	38
101	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1274-1284.	10.7	1,376
102	Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives. Cancer Treatment Reviews, 2017, 59, 109-116.	7.7	122
103	Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients. Anti-Cancer Drugs, 2017, 28, 104-109.	1.4	24
104	Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin. Gynecologic Oncology, 2017, 144, 72-76.	1.4	28
105	1st Evidence-based Italian Consensus Conference on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Ovarian Cancer. Tumori, 2017, 103, 525-536.	1.1	11
106	Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01â€™2014). BMC Cancer, 2017, 17, 493.	2.6	6
107	Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer. Oncotarget, 2017, 8, 77110-77120.	1.8	59
108	Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. Journal of Clinical Oncology, 2017, 35, 3347-3353.	1.6	66

#	ARTICLE	IF	CITATIONS
109	First-Line Systemic Therapy (Chemo/Antiangiogenics). , 2017, , 95-112.		0
110	miRNA-based signature for predicting epithelial ovarian cancer recurrence. Translational Cancer Research, 2017, 6, S232-S234.	1.0	1
111	Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy. Analytical Cellular Pathology, 2016, 2016, 1-5.	1.4	9
112	From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples. Frontiers in Pharmacology, 2016, 7, 110.	3.5	4
113	Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival. Frontiers in Pharmacology, 2016, 7, 123.	3.5	35
114	Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale". Frontiers in Pharmacology, 2016, 7, 287.	3.5	10
115	Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study. Frontiers in Pharmacology, 2016, 7, 331.	3.5	13
116	Development and validation of a microRNA-based signature (MiROvar) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. Lancet Oncology, The, 2016, 17, 1137-1146.	10.7	97
117	Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?. Cancer Treatment Reviews, 2016, 48, 61-68.	7.7	102
118	Recommendations for the implementation of <i>BRCA</i> testing in the care and treatment pathways of ovarian cancer patients. Future Oncology, 2016, 12, 2071-2075.	2.4	21
119	What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO). , 2016, 4, .		0
120	Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. Journal of Clinical Oncology, 2016, 34, 2881-2887.	1.6	114
121	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, December 5th 2015. , 2016, 4, .		0
122	Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncology, The, 2016, 17, 78-89.	10.7	205
123	Long-Term Toxicity and Quality of Life in Patients Treated for Locally Advanced Cervical Cancer. Oncology, 2016, 90, 29-35.	1.9	17
124	Primary surgical cytoreduction in advanced ovarian cancer: An outcome analysis within the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Gynecologic Oncology, 2016, 140, 425-429.	1.4	10
125	Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives. Critical Reviews in Oncology/Hematology, 2016, 97, 335-348.	4.4	22
126	Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. Oncotarget, 2016, 7, 72654-72661.	1.8	15

#	ARTICLE	IF	CITATIONS
127	Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation. <i>Oncotarget</i> , 2016, 7, 82741-82756.	1.8	10
128	How to Design Clinical Trials?. , 2016, , 79-93.		1
129	A miRNA signature assessing ovarian cancer prognosis. <i>Oncoscience</i> , 2016, 3, 308-310.	2.2	2
130	Identification of a distinct population of CD133+CXCR4+ cancer stem cells in ovarian cancer. <i>Scientific Reports</i> , 2015, 5, 10357.	3.3	87
131	The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1094-1095.	2.5	1
132	European Network of Gynaecological Oncological Trial Groupsâ€™ Requirements for Trials Between Academic Groups and Industry Partnersâ€™ First Update 2015. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1328-1330.	2.5	22
133	Low Grade Serous Ovarian Carcinoma: From the molecular characterization to the best therapeutic strategy. <i>Cancer Treatment Reviews</i> , 2015, 41, 136-143.	7.7	76
134	Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 561-568.	10.7	141
135	Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3576-3582.	1.6	97
136	Detection of high mobility group A2 specific mRNA in the plasma of patients affected by epithelial ovarian cancer. <i>Oncotarget</i> , 2015, 6, 19328-19335.	1.8	15
137	The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. <i>Journal of Translational Medicine</i> , 2014, 12, 291.	4.4	32
138	Surveillance Policy for Stage IA Malignant Ovarian Germ Cell Tumors in Children and Young Adults. <i>Journal of Clinical Oncology</i> , 2014, 32, 2814-2815.	1.6	8
139	New biological treatments for gynecological tumors: focus on angiogenesis. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 337-346.	3.1	6
140	Gynecologic Cancer InterGroup (GCIg) Consensus Review for Ovarian and Primary Peritoneal Low-Grade Serous Carcinomas. <i>International Journal of Gynecological Cancer</i> , 2014, 24, S9-S13.	2.5	59
141	Gynecologic Cancer InterGroup (GCIg) Consensus Review for Cervical Adenocarcinoma. <i>International Journal of Gynecological Cancer</i> , 2014, 24, S96-S101.	2.5	41
142	Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 48.	8.6	24
143	Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for) Tj ETQq1 1 0,784314 rgBT /Overl	2.8	9
144	Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 396-405.	10.7	327

#	ARTICLE	IF	CITATIONS
145	Second-Line Chemotherapy in Recurrent Clear Cell Ovarian Cancer: Results from the Multicenter Italian Trials in Ovarian Cancer (MITO-9). <i>Oncology</i> , 2014, 86, 351-358.	1.9	20
146	Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3374-3382.	1.6	302
147	Carboplatin plus paclitaxel scheduling for advanced ovarian cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2014, 15, e250-e251.	10.7	3
148	MITO-11: A randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5503-5503.	1.6	9
149	Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. <i>European Journal of Cancer</i> , 2013, 49, 3831-3838.	2.8	48
150	The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: Data from CALYPSO trial (a GINECO-GCIG study). <i>Gynecologic Oncology</i> , 2013, 130, 289-294.	1.4	34
151	Regulatory T cells, interleukin (IL)-6, IL-8, Vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. <i>BJU International</i> , 2013, 112, 686-696.	2.5	70
152	Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer. <i>Journal of Drug Delivery</i> , 2013, 2013, 1-12.	2.5	48
153	High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer. <i>Journal of Cellular Physiology</i> , 2013, 229, n/a-n/a.	4.1	32
154	A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9845-9850.	7.1	176
155	Testicular and testicular adnexa tumors in the elderly. <i>Anti-Cancer Drugs</i> , 2013, 24, 228-236.	1.4	11
156	Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16).. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA5503-LBA5503.	1.6	35
157	Thinking twice before abandoning first-line chemotherapy in ovarian cancer: report of two cases and literature review. Passing from tri-weekly to weekly regimens. <i>International Journal of Clinical Oncology</i> , 2012, 17, 385-389.	2.2	1
158	Olaparib, PARP1 inhibitor in ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1575-1584.	4.1	30
159	Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 35-46.	4.4	27
160	Chemotherapy in epithelial ovarian cancer. <i>Cancer Letters</i> , 2011, 303, 73-83.	7.2	83
161	Surgical and Medical Treatment of Clear Cell Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1063-1070.	2.5	43
162	A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1347-1353.	2.3	8

#	ARTICLE	IF	CITATIONS
163	Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1338-1342.	6.3	33
164	Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3628-3635.	1.6	182
165	Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. <i>Annals of Oncology</i> , 2011, 22, viii40-viii44.	1.2	30
166	Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study. <i>Oncology</i> , 2011, 81, 104-112.	1.9	24
167	Clinical Trials in Recurrent Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 771-775.	2.5	186
168	European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Pharmaceutical Companies. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 476-478.	2.5	38
169	Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer. <i>Cancer</i> , 2010, 116, 1893-1900.	4.1	144
170	FEZ1/LZTS1 protein expression in ovarian cancer. <i>Journal of Cellular Physiology</i> , 2010, 222, 382-386.	4.1	16
171	Pegylated liposomal doxorubicin combined with carboplatin: A rational treatment choice for advanced ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 73, 23-30.	4.4	14
172	Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. <i>Journal of Clinical Oncology</i> , 2010, 28, 3323-3329.	1.6	500
173	Having progress with upfront chemotherapy in ovarian cancer. Is it still a possible goal?. <i>European Journal of Cancer</i> , 2010, 46, 2140-2142.	2.8	1
174	First-line treatment of advanced ovarian cancer: current research and perspectives. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 47-60.	2.4	84
175	A phase 2 multicenter study of irinotecan and cisplatin as neoadjuvant treatment in patients with locally advanced cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1569-75.	2.5	15
176	Treatment of recurrent epithelial ovarian cancer. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 421.	2.0	24
177	Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4469-4474.	1.6	131
178	Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: Results from the SOCRATES retrospective study. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 233-241.	4.4	32
179	A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1021-1027.	2.3	8
180	Fine-needle cytology of metastatic endometrioid neoplasms: Experience with eight cases. <i>Diagnostic Cytopathology</i> , 2009, 37, 347-352.	1.0	7

#	ARTICLE	IF	CITATIONS
181	New treatment approaches in renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2009, 20, 893-900.	1.4	35
182	Patterns of Care for Radiotherapy in Vulvar Cancer: A Gynecologic Cancer Intergroup Study. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 163-167.	2.5	20
183	A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 229-236.	4.4	72
184	Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. <i>BMC Cancer</i> , 2008, 8, 252.	2.6	44
185	Optimizing Management of Recurrent Epithelial Ovarian Cancer with Non-Platinum-Based Chemotherapy. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2008, 1, 139-140.	0.2	3
186	Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 890-896.	1.6	259
187	Is human hepatocellular carcinoma a hormone-responsive tumor?. <i>World Journal of Gastroenterology</i> , 2008, 14, 1682.	3.3	46
188	Practice Patterns of Radiotherapy in Cervical Cancer Among Member Groups of the Gynecologic Cancer Intergroup (GCIG). <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 485-490.	0.8	29
189	Stop Flow in abdominal and pelvic cancer relapses. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 1284.	3.0	4
190	The prognostic role of pre-chemotherapy hemoglobin level in patients with ovarian cancer. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 1585.	3.0	12
191	Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 59, 243-249.	4.4	48
192	Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2006, 6, 196.	2.6	18
193	Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. <i>BMC Cancer</i> , 2006, 6, 202.	2.6	21
194	Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. <i>BMC Cancer</i> , 2006, 6, 5.	2.6	101
195	Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian Cancer. <i>Oncology</i> , 2006, 71, 320-326.	1.9	30
196	Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 781-791.	4.2	78
197	Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study. <i>Anticancer Research</i> , 2005, 25, 3501-5.	1.1	33
198	Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 2635-2642.	1.6	149

#	ARTICLE	IF	CITATIONS
199	Complete resolution of psoriasis in a patient treated with stealth liposomal doxorubicin and carboplatin for ovarian cancer. <i>Archives of Dermatological Research</i> , 2004, 296, 141-142.	1.9	7
200	Ovarian cancer in the elderly. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 49, 77-86.	4.4	50
201	The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 52, 33-44.	4.4	29
202	Early and Late Complications After Radiofrequency Ablation of Malignant Liver Tumors in 608 Patients. <i>Annals of Surgery</i> , 2004, 239, 450-458.	4.2	336
203	Transcatheter arterial procedures in the treatment of patients with hepatocellular carcinoma: a review of literature. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 46, 285-295.	4.4	6
204	Hepatic Resection and Percutaneous Ethanol Injection as Treatments of Small Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, 63-67.	2.2	71
205	First-Line Chemotherapy With Fluorouracil and Folinic Acid for Advanced Colorectal Cancer in Elderly Patients. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, 228-233.	2.2	31
206	Cyclo-Oxygenase Inhibition in Colorectal Adenomas and Cancer. <i>Journal of Clinical Gastroenterology</i> , 2003, 37, 281-287.	2.2	9
207	Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2002, 35, S109-S114.	2.2	57
208	Single Agents or Combination Chemotherapy for Advanced Ovarian Carcinoma in Elderly Patients: Pro Single Agents. <i>Tumori</i> , 2002, 88, S117-S119.	1.1	0
209	Gynecological Malignancies in Elderly Patients: Is Age 70 a Limit to Standard-Dose Chemotherapy? An Italian Retrospective Toxicity Multicentric Study. <i>Gynecologic Oncology</i> , 2002, 85, 445-450.	1.4	44
210	Effect of Chemotherapy with 5-Fluorouracil on Intestinal Permeability and Absorption in Patients with Advanced Colorectal Cancer. <i>Journal of Clinical Gastroenterology</i> , 2001, 32, 228-230.	2.2	60
211	Subcutaneous Seeding of Hepatocellular Carcinoma After Fine-needle Percutaneous Biopsy. <i>Journal of Clinical Gastroenterology</i> , 2001, 33, 171.	2.2	5
212	Levovist-enhanced Doppler Sonography Versus Spiral Computed Tomography to Evaluate Response to Percutaneous Ethanol Injection in Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2000, 31, 164-168.	2.2	15
213	The Role of Chemotherapy in the Management of Gastric Cancer. <i>Journal of Clinical Gastroenterology</i> , 2000, 30, 364-371.	2.2	16
214	Phase II Study of Cisplatin and Vinorelbine as First-Line Chemotherapy in Patients With Carcinoma of the Uterine Cervix. <i>Journal of Clinical Oncology</i> , 1999, 17, 756-756.	1.6	65
215	Interaction of Putrescine with Nuclear Oligopeptides in the Enterocyte-Like Caco-2 Cells. <i>Digestion</i> , 1999, 60, 255-261.	2.3	20
216	Soluble Interleukin-2 Receptor Levels in Hepatocellular Cancer: a More Sensitive Marker Than Alfa Fetoprotein. <i>Annals of Surgical Oncology</i> , 1999, 6, 178-185.	1.5	37

#	ARTICLE	IF	CITATIONS
217	A Phase I Study of Paclitaxel and Epirubicin, without and with Filgrastim, for the Treatment of Platinum-Resistant Advanced Ovarian Cancer. <i>Oncology</i> , 1999, 56, 267-273.	1.9	4
218	Radiofrequency Ablation of Unresectable Primary and Metastatic Hepatic Malignancies. <i>Annals of Surgery</i> , 1999, 230, 1.	4.2	1,012
219	Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 1997, 9, 283-286.	1.6	30
220	Effect of aspirin on cell proliferation and differentiation of colon adenocarcinoma Caco-2 cells. , 1997, 73, 880-884.		57
221	Constitutive Insulin-like Growth Factor-II Expression Interferes with the Enterocyte-like Differentiation of CaCo-2 Cells. <i>Journal of Biological Chemistry</i> , 1996, 271, 8108-8114.	3.4	35
222	Hypergastrinemia in rats with azoxymethane-induced colon cancers. <i>International Journal of Cancer</i> , 1995, 61, 223-226.	5.1	12
223	Postheparin plasma diamine oxidase in subjects with celiac disease. <i>Gastroenterology</i> , 1991, 100, 583-584.	1.3	2
224	Plasma postheparin diamine oxidase in patients with small intestinal lymphoma. <i>Cancer</i> , 1991, 67, 511-515.	4.1	8
225	Modifications in enterocyte diamine oxidase distribution induced by heparin in the rat. <i>Biochemical Pharmacology</i> , 1989, 38, 47-49.	4.4	16
226	Ornithine decarboxylase and diamine oxidase in human colon carcinoma cell line CaCo-2 in culture. <i>Gastroenterology</i> , 1989, 97, 888-894.	1.3	32
227	Postheparin Plasma Diamine Oxidase in Subjects with Small Bowel Disease. <i>Digestion</i> , 1988, 41, 46-54.	2.3	15
228	Management of Metastatic Endometrial Cancer: Physiciansâ€™ Choices Beyond the First Line. A MITO Survey. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4